Clariant delivers resilient Q3 profitability in a continued challenging market environment
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
- Q3 2024 sales decreased by 1 % in local currency1 to CHF 991 million, with stable pricing and volume growth in Adsorbents & Additives and Care Chemicals offsetting lower Catalysts volumes
- Lucas Meyer Cosmetics delivered strong growth and 2 % of Group sales; integration well on track
- Q3 2024 EBITDA margin before exceptional items of 15.6 % versus 15.9 % in Q3 2023, reflecting lower sales partly offset by effective margin management
- Q3 2024 reported EBITDA margin of 14.0 % below 15.4 % in Q3 2023 due to lower Catalysts volumes and restructuring charges relating to corporate cost measures
- 9M 2024 sales decreased by 5 % in local currency to CHF 3.061 billion while the reported EBITDA margin improved to 15.6 % compared to 15.1 % in the prior year
- Outlook 2024: Profitability confirmed on slightly lower sales; medium-term targets confirmed
“Clariant delivered resilient profitability in the third quarter of 2024 despite a continued challenging environment. We achieved growth in our Adsorbents & Additives and Care Chemicals businesses while maintaining pricing discipline in all businesses. However, lower than expected Catalysts volumes impacted Group sales, EBITDA margin, and our full-year sales outlook. The integration of Lucas Meyer Cosmetics remains well on track, while the sale of the Podari plant assets and the downsizing of the bioethanol business are progressing with lower financial impact than originally anticipated. With continued progress in our performance improvement programs, we confirm our 2024 profitability guidance and reaffirm our medium-term targets.” said Conrad Keijzer, Chief Executive Officer of Clariant.
Third Quarter 2024 Group Discussion
Muttenz, 29 October 2024 – Clariant, a sustainability-focused specialty chemical company, today announced third quarter 2024 sales of CHF 991 million, down 1 % in local currency1 (4 % in Swiss francs) versus the third quarter of 2023. Volumes decreased by 3 %, while pricing was stable across all business units. The acquisition of Lucas Meyer Cosmetics (Scope) had a positive effect of 2 % on Group sales as it continued to deliver strong growth.
Care Chemicals sales increased 1 % organically in local currency as volumes increased slightly, while pricing was stable. The acquisition of Lucas Meyer Cosmetics had a 4 % impact versus Q3 2023. Sales in Catalysts decreased by 20 % in local currency against a high comparison base in the prior year. The challenging global economic environment resulted in continued low customer operating rates, leading to shifts in the regular refill cycles in addition to the anticipated weak new-build activities in the industry. Adsorbents & Additives sales increased by 7 % organically in local currency versus Q3 2023, driven by volume growth in the Additives segments.
In the third quarter, local currency sales in the Europe, Middle East & Africa region increased 2 % (1 % organically) versus Q3 2023, as European engineering partners in Catalysts supplied their global customers from the region and economic activity stabilized at modest levels. Sales in the Americas decreased by 6 % organically with lower sales in Catalysts, which saw strong orders in the prior year partly offset by growth in Adsorbents & Additives and Care Chemicals. Sales in Asia-Pacific were 5 % lower organically in local currency (13 % in China), as growth in Adsorbents & Additives and Care Chemicals only partly compensated the decline for new-build projects in Catalysts.
Group reported EBITDA decreased by 13 % to CHF 139 million, with the corresponding margin of 14.0 % below the 15.4 % margin reported in the third quarter of 2023. Improved operating leverage from higher volumes, particularly in Adsorbents & Additives, and the lower operational impact from sunliquid® could not offset the impact of lower Catalyst volumes. Performance improvement programs resulted in additional cost savings of CHF 7 million in the third quarter. Clariant also identified additional opportunities for targeted cost reduction measures in corporate functions, which resulted in restructuring charges of around CHF 9 million against full-year annual run-rate savings of CHF 6 million. Energy costs increased by 2 %, while raw materials were lower by 5 % year on year. Underlying profitability, as reflected by EBITDA before exceptional items, decreased by 5 % to CHF 155 million. The resilient margin of 15.6 %, versus 15.9 % in Q3 2023, despite lower sales, was achieved through effective margin management and the accretive Lucas Meyer Cosmetics acquisition.
In the third quarter of 2024, Clariant made further progress in the downsizing of activities of the Business Segment Biofuels & Derivatives and resolved related contractual relationships. As a result, Clariant reversed CHF 36 million of non-cash impairments related to right-of-use assets which were originally booked in the fourth quarter of 2023. For 2024, the company now expects a negative operational impact of approximately CHF 10 million (unchanged), total exceptional items of flat to negative CHF 5 million (previously up to negative CHF 15 million). Total cash outflow is expected at CHF 30 - 50 million (previously CHF 80 - 100 million).
Nine Months 2024 Group Discussion
In the first nine months of 2024, sales were CHF 3.061 billion, down 4 % organically in local currency1 (5 % including scope in local currency) and down 8 % in Swiss francs. Price and volume each declined by 2 %, respectively. Scope was net - 1 %, with the contribution from Lucas Meyer Cosmetics being offset by the divestment of the North American Land Oil and Quats business. The currency impact was - 3 %.
Care Chemicals sales decreased by 1 % organically in local currency (- 3 % including scope in local currency), with volume growth unable to fully offset lower pricing due to formula-based price adjustments. In Catalysts, sales decreased by 14 % in local currency with declines in all segments against a strong comparison base. Adsorbents & Additives sales decreased by 2 % in local currency, as slightly higher volumes could not fully offset lower pricing.
In the first nine months of the year, sales decreased by 6 % in the Europe, Middle East & Africa region in local currency, due to continued muted demand in Europe. In the Americas, sales declined by 3 %, despite organic local currency sales growth in Brazil, primarily due to a 2 % reduction in scope. Sales in Asia declined by 6 %, with China also reporting a 6 % decrease, due to the reduced sales in Catalysts.
Group EBITDA decreased by 5 % versus the prior year to CHF 478 million. The corresponding margin increased by 50 basis points to 15.6 % from 15.1 % due to margin management in a deflationary environment and lower sunliquid® costs. Raw material and energy costs decreased by 10 % and 8 %, respectively. The negative operational impact from sunliquid® improved by CHF 26 million to CHF 8 million in the first nine months of 2024. Performance improvement programs resulted in additional cost savings of CHF 27 million in the period.
ESG Update – Leading in sustainability
Clariant’s Scope 1 and 2 total greenhouse gas emissions fell to 0.49 million tons in the last twelve months (September 2023 to September 2024), a decline of 9 % from 0.54 million tons in the full year 2023. The total indirect greenhouse gas emissions for purchased goods and services (Scope 3.1) declined by 4 %, from 2.28 million tons in the full year 2023 to 2.20 million tons in the last twelve months. These results demonstrate continued progress toward reaching the Group’s 2030 emissions reduction targets.
Outlook
For the full year 2024, Clariant anticipates a continued easing of inflationary pressures but no significant economic recovery due to persistent macroeconomic challenges and uncertainties and risks. Therefore, Clariant now expects a low single-digit percent decline in local currency sales. Growth in Care Chemicals, also driven by the acquisition of Lucas Meyer Cosmetics, and in Adsorbents & Additives is expected to only partially offset lower Catalysts sales.
Reported EBITDA margin is expected to be around 16 %. This includes the contribution of the Lucas Meyer Cosmetics acquisition, which is progressing in line with expectations, and reduced sunliquid® costs, offsetting the impact of the lower Catalysts sales and the continued challenging macroeconomic environment in the second half of 2024. Cost savings benefits from performance improvement programs are expected to deliver CHF 33 million in 2024.
Clariant reiterates its expectation that 2025 will be a year of continued improvement in profitability. In 2025, on the basis of an expected 3 % – 5 % local currency sales increase, Clariant expects to achieve an EBITDA margin of 17 % – 18 %, and free cash flow conversion at the targeted level of around 40 %. Clariant remains committed to its medium-term targets as end markets recover and growth normalizes over the next two to three years. Clariant will adopt an agile response to the economic environment and remain resolute in its plans to achieve the medium-term targets.
Clariant will be holding an Investor Day on Monday, 4 November 2024. This in-person event will take place at the Andaz London Liverpool Street Hotel, from 11.00 am to 5.00 pm local time. Presenters will include CEO Conrad Keijzer, CFO Bill Collins, Chief Technology & Sustainability Officer Richard Haldimann, and the Business Presidents Christian Vang (Care Chemicals), Antonio Lara (Lucas Meyer Cosmetics by Clariant), Jens Cuntze (Catalysts), and Angela Cackovich (Adsorbents & Additives). There will be time allocated for Q&A. Investors and analysts can register to attend in person via this link. The event will be recorded and made available on the Clariant website shortly after its conclusion.
1 All references to local currency growth, pricing, volumes, and scope exclude the impact from hyperinflation countries Argentina and Türkiye. All references to currency include a net impact from hyperinflation countries Argentina and Türkiye.